[1] Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma, Retrieved Apr 2, 2020, from https://www.businesswire.com/news/home/20200402005067/en/Kite-Licenses-Antibodies-Establishes-Collaboration-Teneobio-Multiple
[2] Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma, Retrieved Apr 2, 2020, from https://www.fiercebiotech.com/biotech/gilead-s-kite-taps-teneobio-to-build-next-gen-car-ts-for-multiple-myeloma